Rhumbline Advisers Boosts Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Rhumbline Advisers lifted its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 11.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 78,815 shares of the medical device company's stock after acquiring an additional 8,050 shares during the period. Rhumbline Advisers owned approximately 0.16% of AtriCure worth $2,409,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI purchased a new stake in AtriCure during the third quarter valued at about $28,000. Heck Capital Advisors LLC purchased a new position in shares of AtriCure during the 4th quarter valued at about $60,000. KBC Group NV lifted its position in AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after buying an additional 932 shares during the last quarter. R Squared Ltd bought a new stake in AtriCure in the 4th quarter worth approximately $89,000. Finally, Silver Oak Securities Incorporated purchased a new stake in AtriCure in the fourth quarter worth approximately $220,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Trading Down 4.2 %

NASDAQ:ATRC traded down $1.60 during mid-day trading on Thursday, reaching $36.25. 540,000 shares of the company's stock traded hands, compared to its average volume of 665,642. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The company has a 50 day moving average price of $37.77 and a 200-day moving average price of $33.00. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -38.16 and a beta of 1.46.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ATRC shares. Needham & Company LLC restated a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a report on Thursday, February 13th. Piper Sandler boosted their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Stifel Nicolaus upped their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on AtriCure from $40.00 to $51.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Oppenheimer boosted their target price on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $51.56.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.